13 completed, 13 recruiting, 7 terminated, 4 active not recruiting. 44 Phase 2, 14 Phase 1.
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-11-01 | 2026-11-12 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-11-09 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| Epcoritamab-CAR T Cells for Large B-cell Lymphomas Epcoritamab - Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 31 | 2024-09-24 | 2026-05-27 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2026-10-28 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeiGene | 65 | 2021-08-11 | 2026-03-25 |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma DPX-Survivac, Pembrolizumab, CPA - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 102 | 2021-06-18 | 2023-04-07 |
| A Phase I/II Study of Diffuse Large B-cell Lymphoma Rituximab Paclitaxel Ruxolitinib - Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | National Health Research Institutes, Taiwan | 74 | 2021-05-01 | 2021-04-23 |
| Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 41 | 2021-01-18 | 2026-09-11 |
Showing 20 of 44. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (44) · Lymphoma, Mantle-Cell (9) · Lymphoma, Follicular (8) · Lymphoma, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell, Marginal Zone (5) · Burkitt Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (2) · Disease Progression (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphoid (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Large-Cell, Anaplastic (1)
Hemic and Lymphatic Diseases (44) · Immune System Diseases (44) · Immunoproliferative Disorders (44) · Lymphatic Diseases (44) · Lymphoproliferative Disorders (44) · Neoplasms by Histologic Type (44) · Neoplasms (43) · Lymphoma (42) · Lymphoma, B-Cell (38) · Lymphoma, Non-Hodgkin (38) · Disease Attributes (6) · Hematologic Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Chronic Disease (4)
Rituximab (12) · Magnetic Resonance Spectroscopy (10) · Specimen Handling (10) · CT-P10 (9) · Cyclophosphamide (7) · Biopsy (6) · Etoposide (6) · Lenalidomide (6) · axicabtagene ciloleucel (6) · fludarabine (6) · Cytarabine (5) · Carboplatin (4) · Gemcitabine (4) · Ifosfamide (4) · Leukapheresis (4)
National Cancer Institute (NCI) (5) · Fred Hutchinson Cancer Center (4) · University of Washington (4) · City of Hope Medical Center (3) · M.D. Anderson Cancer Center (3) · BeiGene (2) · SWOG Cancer Research Network (2) · University of California, Davis (2) · University of Michigan Rogel Cancer Center (2) · University of Nebraska (2) · Abramson Cancer Center at Penn Medicine (1) · Academic and Community Cancer Research United (1) · Dana-Farber Cancer Institute (1) · David Bond, MD (1) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (1)
United States (39) · China (3) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Hungary (1) · New Zealand (1) · Poland (1) · Romania (1) · Serbia (1) · Spain (1)
Stephen D. Smith (2) · Ajay Gopal (1) · Alex F Herrera (1) · Alexandre V. Hirayama, MD (1) · Andy Davies (1) · Brian T Hess (1) · Caron A Jacobson (1) · Christopher J Melani (1) · David Bond, MD (1) · Elise Chong, MD (1) · Erel Joffe (1) · Grzegorz S Nowakowski (1) · Jennifer Crombie, MD (1) · Jennifer E Amengual (1) · John M Timmerman, MD (1)
PMID 34515338, PMID 27111235, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31331917, PMID 31648294, PMID 32967009, PMID 33942298, PMID 34666344, PMID 36618900, PMID 37774014, PMID 39333103, PMID 39352751, PMID 41595202, PMID 41845899, PMID 42389828
P30CA033572 (3), UM1CA186709 (3), P30CA036727 (2), P30CA093373 (2), U10CA180888 (2), UM1CA186686 (2), 2016 (1), P01CA044991 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA072720 (1), P50CA097274 (1), P50CA107399 (1), R01CA136551 (1)